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1. Introduction 
Vascular dysfunction is a highly complex biological process, and cardiovascular diseases are 
a leading cause of morbidity and mortality in the United States [1]. It is estimated that 
approximately 80 million US adults (>1 in 3) have one or more types of cardiovascular (CV) 
disease, including hypertension, atherosclerosis, and congestive heart failure. CV disease 
has been estimated to account for 34.3% of all deaths in the United States in 2006 [1]. 
Vascular or endothelial dysfunction is caused by many interrelated factors including 
oxidative stress, hypertension, diabetes mellitus, renal disease, smoking, inflammation and 
atherosclerosis.  
In this chapter we will review results from large-scale clinical trials to determine if inhibitors 
of the renin–angiotensin system (RAS), including angiotensin-converting enzyme inhibitors 
(ACEIs) and angiotensin type II receptor blockers (ARBs) and calcium channel blockers 
(CCBs), may have beneficial effects on central aortic pressure (CAP) and the biomarkers 
high-sensitivity C-reactive protein (hsCRP), adiponectin, cystatin C, homeostasis model 
assessment of insulin resistance (HOMA-IR), procollagen, tumor necrosis factor- (TNF-), 
and interleukin-6 (IL-6).  
Biomarkers are playing an increasing role in the study of CV disease and we attempt to 
define their function in improving clinical management and outcomes [2, 3]. By definition, 
biomarkers are objectively measured indicators of biological processes, and to be of use, 
they must be relevant, predictable, accurate, and reproducible [3]. They provide readily 
quantifiable surrogate endpoints and allow accurate assessment of the effects of therapy on 
particular pathological processes, thereby allowing for prompt diagnosis and more timely 
initiation of appropriate treatment, improved monitoring, and treatment augmentation [4].  
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Some of the benefits of inhibiting RAS with ARBs and ACEIs have been shown to be 
independent of blood pressure (BP) reduction [5] [6]. Surrogate biomarkers are diverse, and 
they may provide a viable means of measuring the response to treatment. This chapter will 
focus on the following eight biomarkers, which have been used as predictors of vascular 
outcome in patients with hypertension and those with metabolic syndrome: CAP, hsCRP, 
adiponectin, cystatin C, HOMA-IR, procollagen, TNF-α, and IL-6. 
Anti-inflammatory, anti-atherogenic, and/or improved metabolic homeostasis, independent 
of BP lowering, which is seen with some antihypertensives, may benefit high-risk patient 
populations or those who do not achieve adequate BP control. These include ethnic groups 
such as African Americans, obese patients, and patients with renal disease, metabolic 
syndrome, diabetes mellitus, and/or existing vascular disease. Improvements in 
inflammatory and other biomarkers has been reported with ARBs and ACEIs in obese 
patients with metabolic syndrome [7, 8] and in hypertensive patients with and without type 
2 diabetes mellitus (T2DM) [9, 10]. Similarly, CCBs have been shown to improve markers of 
inflammation in patients with hypertension [11, 12], while -blockers such as nebivolol were 
shown to modify markers of inflammation and obesity in obese African Americans with 
hypertension [13]. As a class, ARBs are known to have anti-inflammatory properties, which 
may contribute to their pharmacologic effects. Biomarker studies in hypertensive patients 
have demonstrated the effects of ARBs on inflammatory and other biomarkers [7, 14], 
including CAP [15, 16], hsCRP [14, 17-19], adiponectin [20], cystatin [21, 22], HOMA-IR [23-
25], procollagen [26-28], TNF-α [29-31], and IL-6 [32-34]. 
This chapter summarizes the role of biomarkers as surrogate endpoints in the treatment of 
hypertensive patients and discusses the evidence for the effects of ARBs and other 
antihypertensive drugs on biomarkers and their correlation with clinical efficacy. The source 
material for this review was derived from a MEDLINE literature search, performed from 
1999 to 2011, to identify published studies investigating the use of selective antihypertensive 
agents using at least one of the eight previously mentioned biomarkers. The agents specified 
in the search were amlodipine, olmesartan medoxomil, combination amlodipine plus 
olmesartan medoxomil, losartan, hydrochlorothiazide (HCTZ), and combination losartan 
plus HCTZ. 
2. A review of anti-hypertensive drugs 
Hypertension is a strong contributor to cardiovascular disease in patients with the 
cardiometabolic syndrome. It has been shown to not only be an independent risk factor, but 
it also contributes to the development of other risk factors for cardiovascular disease. Over 
the last few decades, a number of classes of anti-hypertensive drugs have been used to treat 
hypertension, with the ultimate goal of reducing the incidence of endpoints such as heart 
attacks and stroke. Some of the broad categories of antihypertensives include thiazide 
diuretics, ARBs, ACEIs, CCBs and β-blockers.  
The first step in atherosclerosis is endothelial dysfunction. It has been shown that the RAS is 
involved in the development of atherosclerosis through many different mechanisms 
including increasing oxidative stress, vasoconstriction, inflammation and reduced ability of 
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the endothelium to regenerate itself (reviewed in [35]). The blockage of the RAS through 
ACEIs and ARBs, aids in slowing down the processes of endothelial dysfunction and 
subsequent atherosclerosis. ACEIs reduce angiotensin II production and suppress the 
degradation of bradykinin. This results in reduced oxidative stress, improved vasodilation 
and improved endothelial function [36, 37]. Some common ACEIs include ramipril, 
enalapril, lisinopril, perindopril and fosinopril. The Heart Outcomes Prevention Evaluation 
(HOPE) study evaluated the benefits of ramipril as compared to placebo [38]. Ramipril 
(10mg/day) resulted in a reduction of cardiovascular death (26% RR), nonfatal myocardial 
infarction (MI) (20% RR) and stroke (32% RR). Ramipril was shown to be beneficial in all 
subgroups of patients in the HOPE Study. The Efficacy of Perindopril in Reduction of 
Cardiovascular Events Among Patients with Stable Coronary Artery Disease (EUROPA) 
study, Perindopril Protection Against Recurrent Stroke (PROGRESS) study and the Anglo-
Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) study 
are some other large, outcome trials which also showed a positive effect of ACEIs on 
cardiovascular events and mortality [39-41]. 
ARBs also block the RAS. This is accomplished through blocking of the angiotensin I 
receptor which leads to an upregulation of the angiotensin II receptor and the conversion of 
of angiotensin II to angiotensin (1-7) which has vasodilatory, antioxidant and pro-apoptotic 
properties [42, 43]. Some common ARBs include losartan, telmisartan, valsartan, olmesartan, 
candesartan and irbesartan. Large outcome trials such as the Renal Outcomes with 
Telmisartan, Ramipril, or Both, in People at High Vascular Risk (ONTARGET) study, and 
the Valsartan in Acute Myocardial Infarction (VALIANT) study have shown that ARBs are 
comparable to ACEIs in reducing cardiovascular risk, without the side effect of excess 
coughing that is frequently experienced by patients who are taking ACEIs [44] [45]. 
Combination of ARBs with β-blockers or statins have also shown positive results [46, 47]. 
CCBs are another class of antihypertensives which provide similar blood pressure lowering 
effects of ACEIs and ARBs, but they provide better protection against stroke and heart 
failure [48]. CCBs inhibit the flow of extracellular calcium through ion-specific channels that 
span the cell wall. This causes vascular smooth muscle cells to relax and thereby results in 
vasodilation, blood pressure lowering and reduced peripheral arterial resistance. 
Commonly prescribed CCBs include amlodipine, benidipine, azelnidipine and manidipine.  
β-blockers are another group of antihypertensives which are divided into two main 
categories. Traditional (non-vasodilatory) β-blockers such as atenolol, metropolol and 
propanolol reduce blood pressure by reducing cardiac output [49]. These β-blockers are 
effective at lowering brachial blood pressure, however data from studies including the 
Conduit Artery Function Evaluation (CAFÉ) study suggests that these compounds do not 
adequately control central aortic pressure [50]. This can then lead to an increase in vascular 
events including stroke [51]. Additionally, these agents have been shown to increase plasma 
triglyceride levels [52] and the risk of new-onset diabetes by about 20-30% [53, 54]. The other 
group of β-blockers are the vasodilatory β-blockers which includes labetalol, carvediol and 
nebivolol. These drugs reduce systemic vascular resistance while maintaining cardiac 
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output. Additionally, these agents do not negatively affect glycemic control and may even 
provide beneficial metabolic effects [55-57]. 
Diuretics include HCTZ , chlorthalidone and the loop diuretics such as furosemide. 
According to the Joint National Committee on Prevention, Detection, Evaluation , and 
Treatment of High Blood Pressure (JNC 7) guidelines, diuretics are recommended as the 
first line of therapy for hypertension [58]. Chlorothalidone is more potent at 25mg dosing 
than 50mg of HCTZ. Also, chlorothalidone has been shown to improve cardiovascular 
outcomes [59]. Certain subpopulations, including diabetics, the elderly and blacks have 
lower renin levels and they respond favorably to diuretic therapy [60]. Diuretics, 
particularly HCTZ, are often combined with antihypertensives from another class, such as 
ARBs and ACEIs, to provide enhanced therapeutic benefits [61]. 
The newest category of anytihypertensives include direct renin inhibitors (DRIs). Aliskiren 
is the most common DRI. This class of drugs works by inhibiting the first rate-limiting step 
in the RAS, resulting in a more complete inhibition of the RAS cascade as compared to 
ACEIs and ARBs [62]. Additionally, DRIs reduce the production of aldosterone, which in 
addition to its sodium retension effects, also is a mediator in oxidative stress and 
inflammation [63] [64]. The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) 
study and the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial show that 
aliskiren has renal and cardio protective effects in addition to blood pressure regulation [65, 
66]. 
3. Role of biomarkers and mechanisms in specific patient groups 
3.1. CAP 
While brachial BP is easily measured and has been shown to be predictive of CV morbidity 
and mortality, it is an imperfect surrogate measure of CAP. Peripheral systolic BP (SBP) 
measured at the brachial artery does not accurately reflect CAP, particularly in youths, as a 
result of peripheral amplification of the pulse pressure wave [67-69]. This amplification 
difference decreases with age and arterial stiffness. Central aortic systolic pressure or pulse 
pressure has been shown to be a powerful and more robust predictor of end organ damage 
and CV mortality than brachial BP, irrespective of whether the central pressures were 
derived from noninvasive pulse wave analysis or measured directly during routine 
catheterization [68]. Although techniques have been developed to a stage where direct 
noninvasive measurement of CAP could be readily applied to routine clinical practice, the 
studies conducted to-date, assessing the predictive value of CAP, have been relatively small. 
Thus, additional data from large interventional studies of clinical outcomes and larger-scale 
longitudinal epidemiological studies of clinical outcomes are required to confirm the utility 
of CAP as a predictor of vascular risk before it becomes part of routine clinical practice [67-
69]. 
Noninvasive assessment of the central pulse pressure waveform is performed by 
applanation tonometry, which involves applying a pressure sensor (tonometer) with mild 
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pressure over the radial or carotid artery. The recorded waveform is then used to 
algorithmically derive central pressure indices from a peripheral brachial BP measurement 
[69]. In addition, aortic pulse wave velocity (PWV), which is usually recorded between the 
carotid and femoral arteries, is used to determine vessel distensibility; the velocity of the 
pulse wave increases with decreasing vessel distensibility (increased arterial stiffness) [67]. 
Increased PWV, an indication of arterial stiffness, appears to be associated with endothelial 
dysfunction, inflammation, and atherosclerosis, and has been shown to be an independent 
predictor of coronary events and CV mortality [67]. Hence, arterial stiffness is an emerging 
biomarker for therapeutic interventions. 
3.2. hsCRP 
C-reactive protein (CRP), an acute phase reactant predominantly produced in the liver in 
response to IL-6, interleukin-1β, and TNF-α, is a marker of the general inflammatory 
response. Current technology permits the quantification of CRP through a high-sensitivity  
assay, therefore this marker is referred to as hsCRP. Epidemiological studies have 
established that individuals with higher levels of hsCRP have increased CV risk [70]. The 
nature of the relationship between hsCRP and CV disease is unclear, but hsCRP provides a 
useful measure of risk and the effects of interventions [70, 71].  
Studies have shown a continuous independent association between serum CRP levels and 
elevated BP [72]. In elderly, normotensive individuals, higher baseline CRP levels were 
associated with a higher incidence of new-onset hypertension after 2 years [73]. Moreover, 
in apparently healthy adults representative of the US population, a 10-mmHg increase in 
pulse pressure was associated with significant increases of 12%–15% in the odds of having 
an elevated CRP level, independent of SBP or diastolic BP (DBP), or demographic factors 
[74]. There are even suggestions that hsCRP may be a better marker of coronary artery 
disease (CAD) than low-density lipoprotein cholesterol (LDL-C) [2, 75]. Evidence suggests 
that inhibition of the RAS with certain agents, particularly ARBs and ACEIs, may improve 
CV outcomes by reducing vascular inflammation and remodeling independently of BP 
reductions [76]. 
3.3. Adiponectin 
Adiponectin is one of the adipocyte-derived hormones that has profound anti-inflammatory 
and anti-atherogenic properties. It is also thought to play an important role in the 
modulation of glucose and lipid metabolism [2, 77]. Reduced adiponectin levels have been 
noted in males, obese subjects, and patients with hypertension, CAD, or T2DM [78]. 
Reduced adiponectin levels are predictive of CAD and MI [79]. Animal studies have shown 
that increased adiponectin levels are protective against atherosclerosis, while clinical studies 
with antihypertensive drugs, including ARBs, ACEIs, and CCBs, have associated 
improvements in BP and insulin resistance with increased adiponectin levels [78, 80]. In 
obese subjects, serum adiponectin levels were inversely associated with intima-media 
thickness, a surrogate measure of subclinical atherosclerosis, and positively associated with 
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arterial compliance [79]. The mechanism behind the beneficial effects of adiponectin is 
uncertain; one hypothesis suggests that adiponectin increases nitric oxide activity, thereby 
inhibiting platelet activation, while another hypothesis suggests it suppresses monocyte 
activation [78].  
3.4. Cystatin C 
The serum cystatin C level directly correlates with the glomerular filtration rate (GFR) and is 
produced constantly, independent of muscle mass, age, or sex. It is therefore an easily 
obtained biomarker for renal dysfunction that may be more reliable than measurement of 
creatinine levels in certain patient populations, particularly in children  [81-83]. However, 
there are concerns over the cost of the immunoassay, intraindividual variability, and its 
sensitivity in transplant patients or its suitability in patients with cancer, where cystatin C 
production may vary [82]. Notably, a study in patients after heart transplantation found that 
cystatin C was superior to creatinine as a prognostic indicator of early renal dysfunction 
during 4 years of follow-up [84]. 
Cystatin C is a predictor of CV morbidity and mortality, and it has been suggested that this 
association may be independent of renal function [85, 86]. In one study, cystatin C, but not 
creatinine or GFR, was closely associated with left ventricular (LV) mass in patients with 
hypertension, suggesting utility as a marker for cardiac hypertrophy [86]. 
3.5. HOMA-IR 
HOMA-IR is a mathematical model prediction that provides an accurate quantitative 
assessment of insulin resistance [87], which is associated with hypertension, obesity, and 
diabetes, and an increased risk of CAD [88]. 
Many CV drugs adversely affect glucose and lipid homeostasis, and insulin resistance is an 
important mediator of these adverse effects on glucose metabolism [88]. Direct RAS 
inhibitors (ARBs and ACEIs) and some other antihypertensives provide beneficial effects in 
terms of glucose homeostasis [88]. 
3.6. Procollagen 
Collagen fractions in the extracellular matrix are intimately involved in the atherosclerotic 
process and the vascular remodeling that occurs in CV disease [89]. There is evidence that 
altered collagen metabolism (eg, elevated serum levels of tissue inhibitor of 
metalloproteinase-1) is associated with hypertension [89], and that plasma markers of 
collagen metabolism are positively correlated with arterial stiffness measured by PWV in 
hypertensive patients with LV hypertrophy [90]. 
Therefore, measurement of serum procollagen fractions as indicators of myocardial fibrosis 
may be useful in the clinical assessment of CV risk [91]. 
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3.7. TNF- 
TNF-α is a marker of inflammation and is believed to promote the development of insulin 
resistance and hyperinsulinemia, and thereby affect BP [29]. TNF-α is released from mast 
cells and macrophages in the myocardial endothelium during acute MI, and from 
cardiomyocytes during persistent ischemia. The released TNF-α contributes to ischemic 
and/or reperfusion injury and is believed to contribute to cardiac contractile dysfunction 
after MI via a local inflammatory reaction [31]. Surprisingly, low levels of TNF-α may be 
beneficial and display a cardioprotective effect, reducing infarct size [31]. TNF-α is also 
believed to play a role in the development of atherosclerosis by up-regulating cell surface 
receptors for advanced glycation end products that promote the release of inflammatory 
mediators in the endothelium [30]. The differential effects are possibly related to which of 
the two tumor necrosis receptor types (TNF-R1 or TNF-R2) the TNF-α molecule interacts. 
3.8. IL-6 
IL-6 is an inflammatory cytokine that, along with TNF-α, is one of the main inducers of 
acute phase reactants, such as CRP. It has been positively correlated with CV risk. For 
instance, in elderly subjects without known CV disease, serum levels of IL-6 were 
significantly associated with CAD, stroke, and congestive heart failure events, and to a 
greater extent than CRP or TNF-α levels [92]. Similarly, in older men without CAD, IL-6 was 
found to be more discriminating than CRP and fibrinogen in predicting a first coronary 
artery ischemic event, being associated with MI/coronary death but not CAD endpoints 
(angina) [33]. However, not all studies have found strong correlations between IL-6 and 
CAD [34]. 
4. Antihypertensive drugs: benefits beyond just blood pressure lowering 
Clinical evidence that many current antihypertensive agents have a beneficial effect on 
putative biomarkers of CV pathology or risk continues to accumulate and indicates that not 
all drugs or patient subpopulations are equal.  
4.1. CAP 
Of the various antihypertensive drug classes, RAS inhibitors (ARBs and ACEIs) and CCBs 
generally appear to have greater effects on CAP than -blockers and thiazide diuretics. 
Despite similar brachial BP reductions, the combination of amlodipine plus perindopril was 
associated with greater reductions in CAP than atenolol plus a thiazide diuretic [93]. 
Lisinopril also significantly reduced central SBP, central pulse pressure, and the 
augmentation index, while bisoprolol only significantly lowered central DBP and actually 
increased the augmentation index [94]. The combination of olmesartan and azelnidipine was 
compared to olmesartan and amlodipine [95]. While both combinations had similar brachial 
BP lowering effects, there was a greater reduction in CAP with the olmesartan/azelnidipine 
combination. Another study showed significant reductions in both brachial and central BP 
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reductions with different drug classes in the following order: CCBs > diuretics (HCTZ) > 
ACEIs [96]. -blockers did not significantly lower peripheral or central BP.  
Similar brachial BP and CAP reductions were achieved with valsartan plus HCTZ versus 
amlodipine; however, valsartan plus HCTZ provided a greater reduction in arterial stiffness 
(estimated by aortic PWV) [97]. Reductions in central SBP were greater with fosinopril plus 
HCTZ than with indapamide or amlodipine; this correlated with 24-hour and nighttime SBP 
reductions, but not with seated cuff SBP [98].  
Recent studies have shown that PWV is significantly reduced with candesartan or 
benidipine treatment, as compared to amlodipine [99, 100]. Arterial stiffness, measured 
through cardioankle vascular index was significantly decreased with combination of 
olmesartan and azelnidipine, but not with olmesartan monotheraphy [101]. However, 
arterial index decreased significantly with monotheraphy and combination therapy in this 
study. On the other hand, another recent study showed that monotheraphy with olmesartan 
does significantly decrease arterial stiffness [102]. 
The effects of antihypertensives on flow mediated dilation (FMD) has also been measured. 
Olmesartan has been shown to positively impact FMD and while amlodipine treatment has 
no effect on FMD [103], the combination of amlodipine and atorvastatin has significant 
improvements on this marker, even more than atorvastatin alone [104]. Another study 
found the same effects of amlodipine and atorvastatin combination on patients with 
hypertension and hyperglycemia [105]. The combination of amlodipine and valsartan was 
also found to improve FMD in diabetics with early hypertension, even more than the effects 
of the individual drugs [106]. 
4.2. hsCRP 
Several antihypertensive drug classes, such as ARBs, ACEIs, and CCBs, lower serum 
hsCRP in addition to BP, indicating a reduction in the inflammatory processes involved in 
the progression of atherosclerosis. ARBs, in particular, seem to have a strong depressor 
effect on this marker of inflammation. Patients with chronic kidney disease (CKD), who 
have higher baseline levels of inflammation than control subjects with normal renal 
function, displayed significant reductions in hsCRP and brachial BP with olmesartan 
medoxomil treatment [107]. In a small study of 10 patients with mild-to-moderate 
hypertension, olmesartan medoxomil did not reduce BP significantly, but did produce 
significant reductions in hsCRP and appeared to improve myocardial function 
independent of BP lowering [19]. In another study, hsCRP levels significantly dropped in 
hypertensive patients who were treated with olmesartan for 6 month [102]. In non-
diabetic patients with hypertension and the metabolic syndrome, both olmesartan 
medoxomil plus amlodipine and olmesartan medoxomil plus HCTZ effectively reduced 
BP and CRP with no differences between groups. However, olmesartan plus amlodipine 
produced greater reductions in all other inflammatory markers [108]. Olmesartan 
treatment was compared to candesartan treatment in hypertensive patients with T2DM 
[109]. BP and hsCRP reductions were similar in both treatment groups. In a separate 
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study, these researchers also found that monotherapy with either losartan or ramapril is 
equally beneficial in lowering hsCRP [109]. 
In a study comparing the CCB azelnidipine or the thiazide diuretic trichlormethiazide 
added to an ARB, the ARB plus azelnidipine combination produced significantly greater 
reductions in hsCRP than the ARB plus thiazide combination; this reduction mirrored the 
BP-lowering effects [110]. Similar data were shown in a 4-month crossover study comparing 
olmesartan medoxomil plus azelnidipine or trichlormethiazide [111]. Azelnidipine was 
shown to be superior to amlodipine with regards to hsCRP lowering in nondiabetic 
hypertensive patients and the beneficial effects of azelnidipine also included improved 
glucose tolerance and insulin sensitivity [112]. When combined with atorvastatin, 
amlodipine therapy reduces plasma hsCRP significantly [104]. In the recent Effects of 
Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and 
Metabolic, Inflammatory and Prothrombotic Markers in Hypertensive Patients with 
Metabolic Syndrome: the MARCADO Study, a number of monotherapies (manidipine, 
amlodipine, teimisartan) and combination therapy (manidipine/lisionpril) were compared 
for treatment of non-diabetic, hypertensive patients with the metabolic syndrome. Levels of 
hsCRP reduced with all of these treatments, but the most significant reduction was with the 
manidipine/lisinopril combination therapy [113]. Comparison of 12 weeks of combination 
therapy with enalapril plus add-on losartan with higher dose enalapril monotherapy 
showed a significant reduction in hsCRP with combination therapy, but not with high-dose 
enalapril alone; BP reductions were significant and similar in both groups [114]. In another 
study, patients who were on olmesartan therapy received additional HCTZ or azelnidipine 
therapy for 24 weeks. HsCRP levels dropped significantly with the azelnidipine add-on 
therapy but there was no change with HCTZ therapy [115].  
Evidence suggests that ARBs may differ in their anti-inflammatory effects. For instance, in 
patients with CAD, olmesartan medoxomil and valsartan both produced significant 
reductions in BP, but only olmesartan medoxomil induced a significant reduction in hsCRP 
[116]. Losartan has also been shown to reduce hsCRP in newly diagnosed hypertensive 
patients who are at CV disease risk [117]. Studies comparing the hsCRP-lowering effects of 
ARBs and CCBs have shown variable results. One study found no difference in hsCRP 
reductions after 8 weeks of therapy with losartan or amlodipine regimens [118]. The effects 
on hsCRP and other inflammatory markers did not explain the greater improvements in 
insulin sensitivity seen with ARBs over CCBs. However, in patients with hypertension and 
other CV risk factors, therapy with valsartan plus HCTZ was significantly more effective 
than amlodipine in reducing hsCRP. These biomarker results correlated with BP reductions 
[119]. HsCRP improvement did not correlate with endothelial function in a study comparing 
candesartan with amlodipine; both treatments significantly improved endothelial function 
(assessed by changes in forearm blood flow in reactive hyperemia), whereas significant 
reductions in hsCRP levels were seen only with candesartan and not amlodipine therapy 
[120]. The study investigators concluded that the anti-inflammatory effects observed with 
candesartan may be related to observed improvement in insulin sensitivity. In a study of 
patients with CAD, treatment with irbesartan did not lower hsCRP levels. [121] The lack of 
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effect of irbesartan may have been due to low levels of hsCRP at study baseline. Patients 
were also receiving statin and aspirin therapy, which also lower levels of this marker. In a 
recent study, olmesartan reduced hsCRP levels in patients with essential hypertension while 
amlodipine had no effects on hsCRP [103]. 
As with ARBs, CCBs seem to differ in their ability to reduce inflammatory markers. In 
hypertensive patients with the metabolic syndrome, similar significant reductions in hsCRP 
and BP were seen with manidipine and amlodipine, but these data did not correlate with 
changes in other biomarkers, such as adiponectin, HOMA-IR, and TNF-α, which showed 
greater improvements with manidipine than with amlodipine [122]. In a different study in 
patients with arterial hypertension and insulin resistance who were already receiving at 
least two antihypertensive agents, neither moxonidine nor amlodipine showed significant 
changes in hsCRP, whereas both treatments resulted in significant BP lowering [123]. 
Adding a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor 
(atorvastatin) to amlodipine therapy produced significantly greater reductions in BP and 
hsCRP than was seen with amlodipine alone [124], but losartan plus simvastatin achieved 
similar reductions in hsCRP compared with losartan or simvastatin alone [47]. BP 
reductions were significantly greater with losartan or losartan plus simvastatin than with 
simvastatin alone. The combination of rosuvastatin and a number of ARBs was studied as 
treatment in adults with the metabolic syndrome [125]. While rosuvastatin and telmisartan 
reduced hsCRP by 44% after 24 weeks of therapy, there was less reduction in hsCRP with 
the combination of rosuvastatin  and irbesartan or rosuvastatin and olmesartan. 
These observations suggest that RAS antagonists such as ARBs and ACEIs have a significant 
anti-inflammatory effect, and there may be variations within these classes. As diseases such 
as diabetes mellitus and atherosclerosis are inflammatory processes, the clinical benefits 
seen with these classes of antihypertensives may be a combination of the suppression of 
inflammation and the reduction of BP. 
4.3. Adiponectin 
Studies assessing the effect of the selected antihypertensive drugs on the serum levels of 
adiponectin are discussed here. Antihypertensive agents do not uniformly influence 
metabolic parameters in patients with hypertension. In a comparison of telmisartan and 
irbesartan in obese, insulin-resistant, hypertensive patients, increases were significantly 
greater with telmisartan, although both treatments resulted in significant increases in 
adiponectin levels [126]. Adiponectin changes correlated inversely with changes in BP for 
telmisartan, but not for irbesartan. The investigators speculate that the differences between 
the two agents may be partly due to partial peroxisome proliferator-activated receptor- 
(PPAR-γ) agonist activity exhibited by telmisartan, although a study by Kintscher et al in 
14,200 patients confirmed that irbesartan also activates PPAR-γ [127]. Despite similar 
reductions in BP, olmesartan medoxomil plus amlodipine produced significant increases in 
adiponectin levels in patients with hypertension and the metabolic syndrome, whereas 
olmesartan medoxomil plus HCTZ did not [108]. The increase in adiponectin correlated 
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with a lower risk for developing T2DM and paralleled reductions (improvements) in 
HOMA-IR index and fasting plasma insulin levels. 
In nondiabetic, proteinuric patients, treatment with losartan plus HCTZ reduced BP, 
proteinuria, and LDL-C, and increased adiponectin, but the change in adiponectin 
correlated with adverse reductions in high-density lipoprotein cholesterol (HDL-C) levels 
[128]. In a crossover study that investigated possible factors to explain improvements in 
insulin sensitivity with ARB therapy compared with CCB therapy in patients with 
hypertension, between group differences were not noted for increases in adiponectin levels 
or reductions in BP after 8 weeks of therapy with losartan or amlodipine [118]. In contrast, 
although both telmisartan and amlodipine increased adiponectin levels in patients with 
hypertension and T2DM, the increases were higher with telmisartan than with amlodipine 
[129]. Both groups showed a similar significant decrease in BP. Similarly, in patients with 
prediabetes, losartan produced greater increases in adiponectin than a CCB, whereas BP 
reduction was similar and significant in both groups [130]. Within CCBs, candesartan, but 
not olmesartan therapy, over the period of a year resulted in increased adiponectin and 
insulin sensitivity in T2DM hypertensive patients, even though BP lowering was similar in 
both treatment groups [109]. When compared to the ACEI ramipril, losartan treatment 
significantly improved adiponectin levels and overall metabolic parameters while ramipril 
had no effect on adiponectin or any other metabolic markers [131]. In obese hypertensive 
patients, telmisartan, but not losartan raised serum adiponectin levels [132].  
ARBs and statins have additive effects on adiponectin. Losartan plus simvastatin or losartan 
alone resulted in significantly greater increases in adiponectin levels from baseline than with 
simvastatin alone [47]. This correlated with BP reductions, which were greater with losartan 
or losartan plus simvastatin than with simvastatin alone. A correlation was also observed 
with LDL reductions, which were greater with simvastatin or simvastatin with losartan 
relative to losartan alone. 
There were no changes in adiponectin levels with the aldosterone blocker spironolactone or 
the CCB amlodipine in patients with diabetic nephropathy or in controls. However, 
spironolactone, but not amlodipine, increased adiponectin in a subgroup of patients with 
poor baseline glycemic control, i.e. glycosylated hemoglobin (HbA1c) ≥8%. A significant 
decrease in SBP, but not DBP, was observed in both treatment groups [133]. This link 
between the renin-angiotensin cascade and aldosterone suggests a possible mechanism by 
which spironolactone provides an increased level of adiponectin in hyperglycemia.  
In a comparison of enalapril, metoprolol, amlodipine, and indapamide, no changes in 
adiponectin level were seen with enalapril, amlodipine, or metoprolol, whereas a reduction 
in adiponectin was seen with indapamide. This reduction in adiponectin with the thiazide-
like diuretic correlated with increased insulin resistance [134]. In a comparison of 
metoprolol, amlodipine, ramipril, doxazosin, and valsartan in hypertensive patients with 
the metabolic syndrome, both ramipril and valsartan resulted in significantly higher 
increases in adiponectin than the other regimens; adiponectin levels inversely correlated 
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with SBP [135]. In a study comparing manidipine, amlodipine, telmisartan, and the 
combination therapy of manidipine and lisinopril, adiponectin levels increased with all of 
the treatments except amlodipine. The greatest increase in adiponectin was seen with 
manidipine [113]. The combination of amlodipine and atorvastatin resulted in a greater 
increase in adiponectin than treatment with amlodipine alone [104]. Similar results were 
seen in patients with hypertension and hyperglycemia that were treated with amlodipine 
and atorvastatin [105].  
In a small study in patients with hypertension, ramipril, candesartan, and amlodipine were 
associated with greater increases in adiponectin levels while thiazide and atenolol were 
associated with a decrease in adiponectin. There were no correlations with BP lowering, 
which was greatest with atenolol, amlodipine, and candesartan therapies than with ramipril 
[136].  
Unlike the situation with hypertensive, obese, or diabetic patients, where adiponectin levels 
are reportedly reduced, the levels of adiponectin are raised in patients with renal disease 
when compared with healthy controls. Thus, in patients with renal disease, a positive 
correlation between adiponectin and insulin resistance is seen, and increased adiponectin 
levels are associated with increased all-cause and CV mortality (the opposite of that seen in 
obese patients or those with T2DM without renal disease). Paradoxically, short-term 
losartan therapy in patients with T2DM nephropathy was associated with a significant 
decrease in adiponectin levels compared with amlodipine therapy [137]. 
Adiponectin, secreted by fat cells, regulates the insulin response and has a favorable effect 
on glucose and lipid metabolism. Insulin resistance is a hallmark for the progression of 
vascular disease. The quantitative changes in adiponectin provide insight into how 
antihypertensive agents such as ARBs may be effective in attenuating or reversing the 
pathogenesis of atherosclerosis and diabetes mellitus. 
4.4. Cystatin C 
Only three studies have assessed the effect of the selected antihypertensive drugs on serum 
cystatin C levels. In one study, a significant decrease in cystatin C with olmesartan 
medoxomil therapy correlated with improvements in BP, LV mass index, and LV 
hypertrophy at 6 months [138]. Another study found that cystatin C levels decreased in 
patients who were on olmesartan or olmesartan with HCTZ, but in this study, there was no 
correlation between cyctatin C and BP levels [139]. However, the third study found no 
significant decrease in cystatin C with enalapril/losartan combination therapy or with high-
dose enalapril, despite significant reductions in BP [114].  
The use of cystatin C as an early marker for CKD may be helpful in longitudinal follow-up 
analyses. The findings in the above studies are preliminary but suggest that BP reduction 
may be associated with lower cystatin C levels. It is too early to determine whether 
inhibition of the RAS (in the form of ACEIs or ARBs) may have an effect on cystatin C that is 
superior to other antihypertensive drugs. 
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4.5. HOMA-IR 
HOMA-IR is a model and calculation to determine quantification of insulin resistance. 
Antihypertensive drugs appear to have differing effects on insulin resistance, with ARBs 
foremost among those improving insulin sensitivity, although considerable variability has 
been observed and not all ARBs may be equal in this regard. RAS inhibitors generally have 
greater effects on glucose homeostasis than CCBs, which are usually considered to have 
neutral effects. 
In hypertensive patients, a significantly greater reduction in HOMA-IR was seen with 
losartan/amlodipine therapy than with high-dose amlodipine [118]. The addition of losartan 
therapy to chronic heart failure patients who were on ACEIs resulted in a reduction of 
HOMA-IR as well as inflammatory cytokines after 24 weeks of therapy [140]. The 
MARCADOR Study compared the effects of manidipine, amlodipine, telmisartan, and 
manidipine combined with lisinopril. While BP lowering was similar with all of these 
treatments, HOMA-IR levels improved in all of the treatments except for amlodipine, and 
the greatest change in HOMA-IR was seen with manidipine treatment [113]. In contrast to 
previous results, both losartan and telmisartan had neutral effects on insulin resistance in 42 
hypertensive patients with the metabolic syndrome, with no significant reductions in 
HOMA-IR in either group; BP reductions were similar for both ARBs [141]. In a more recent 
study, obese hypertensive patients were treated with telmisartan or olmesartan. While 
olmesartan improved BP levels, only telmisartan improved insulin glucose and HOMA-IR 
levels in addition to improving BP levels [25]. Others have also shown that telmisartan 
therapy helps to reduce HOMA-IR levels as compared to other ARBs and CCBs [132, 142]. 
Researchers studied the effects of irbesartan as compared to olmesartan in obese 
hypertensive females and found that while both treatments improved BP and lipid levels, 
only olmesartan resulted in HOMA-IR changes [143]. Olmesartan was also found to reduce 
HOMA-IR in hypertensive patients with sleep disordered breathing. Positive changes in BP 
level and left ventricular ejection fraction were also seen in these patients with olmesartan 
treatment [144].  
Non-diabetic CKD patients have a high prevalence of insulin resistance, metabolic 
syndrome, and chronic inflammation. Treatment with olmesartan medoxomil for 16 weeks 
was associated with a significant reduction in HOMA-IR, along with reductions in markers 
of inflammation [107]. Losartan therapy was associated with improvements in fasting 
plasma insulin and HOMA-IR in patients with T2DM nephropathy, in parallel with 
reductions in adiponectin levels [137]. Both olmesartan medoxomil and telmisartan were 
shown to improve HOMA-IR in patients with nonalcoholic fatty liver disease and chronic 
hepatitis C, conditions with a greater incidence of insulin resistance than other liver diseases 
[145]. 
In a study investigating the effect of combination therapy with amlodipine plus olmesartan 
medoxomil on HOMA-IR in hypertensive patients with the metabolic syndrome, HOMA-IR 
was significantly reduced with olmesartan medoxomil/amlodipine, whereas no significant 
changes were seen with olmesartan medoxomil/HCTZ. The reductions in the HOMA-IR 
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index strongly correlated with the increases in adiponectin level in the group treated with 
olmesartan medoxomil/amlodipine [108]. 
In a crossover study of amlodipine with or without atorvastatin therapy in obese patients 
with hypertension and normal lipid profiles, combination amlodipine/atorvastatin therapy 
produced a significantly greater reduction in HOMA-IR than amlodipine monotherapy; 
there was no correlation with BP reduction with either treatment [29]. The combination of 
rosuvastatin with telmisartan significantly lowered HOMA-IR and fasting serum insulin 
levels in metabolic syndrome patients, but when irbesartan or olmesartan was combined 
with rosuvastatin, HOMA-IR and fasting insulin levels increased [125]. In non-diabetic 
patients with the metabolic syndrome, manidipine, but not amlodipine, significantly 
reduced HOMA-IR [122]. 
In patients with hypertension and insulin resistance, neither moxonidine nor amlodipine 
produced changes in HOMA-IR. Both treatments significantly lowered BP and increased 
HDL-C, but only moxonidine reduced serum triglycerides. Neither drug affected serum 
CRP levels [123].  
In patients with T2DM nephropathy, losartan, but not amlodipine, reduced HOMA-IR from 
baseline, but the between-group difference was not significant. However, other parameters 
of glucose metabolism (eg, fasting blood glucose, HbA1c, and insulin sensitivity) were 
improved to a greater extent with losartan than with amlodipine [146]. In patients with 
hypertension and T2DM, telmisartan resulted in greater improvements in HOMA-IR than 
amlodipine [129]. 
Similar results with losartan and amlodipine were seen in patients with prediabetes, with 
greater improvements in HOMA-IR with losartan than with amlodipine; the two agents 
resulted in similar BP reductions [130]. 
In a study in hypertensive patients, both candesartan and amlodipine significantly 
improved endothelial function, but significant decreases in HOMA-IR and CRP were only 
observed with candesartan [120]. 
In a comparison of losartan and amlodipine in Japanese patients with hypertension, with or 
without diabetes, losartan provided greater increases in adiponectin than amlodipine. These 
increases correlated with HOMA-IR changes [147]. 
In agreement with the adiponectin results discussed earlier, indapamide treatment 
increased HOMA-IR in patients with hypertension, whereas no changes in HOMA-IR were 
seen with enalapril, metoprolol, or amlodipine [134]. In patients with hypertension and the 
metabolic syndrome, doxazosin, amlodipine, ramipril, and valsartan produced significant 
reductions in HOMA-IR, whereas no changes were seen with metoprolol [135]. 
Insulin resistance is a central force in the pathogenesis of vascular diseases, and HOMA-IR 
provides a reasonable assessment of the quantification of insulin resistance. Several long-
term clinical studies have demonstrated the clinical benefit of ARBs in diabetic kidney 
disease, both in late stage [the Reduction of Endpoints in NIDDM with Angiotensin II 
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Antagonist Losartan (RENAAL) study and the Irbesartan Diabetic Nephropathy Trial 
(IDNT) study] and early stage [The Effect  of Irbesartan on the Development of Diabetic 
Nephropathy in Patients with Type 2 Diabetes (IRMA-2) study]. The role of HOMA-IR may 
be beneficial in clinical practice, and quantitative and longitudinal analysis could provide 
long-term follow-up of disease management. 
4.6. Procollagen 
Several studies have assessed the effect of antihypertensive agents on procollagen fractions 
as a marker of atherogenesis and vascular remodeling. Valsartan and ramipril, but not 
amlodipine, were associated with reductions in procollagen. Despite similar BP lowering, 
valsartan and ramipril were more effective than amlodipine in preventing new episodes of 
atrial fibrillation [148]. 
Another study showed a significant difference in procollagen type I carboxy-terminal 
peptide (PICP) lowering between candesartan and amlodipine. Although BP control was 
similar, 24-hour SBP was significantly lower and LV mass index significantly decreased 
with amlodipine, while the effect of ARBs on procollagen indicate that they protect against 
CV fibrosis and renal injury [149]. 
There were no differences in procollagen markers with losartan- or atenolol-based regimens 
after the first year of treatment; changes in PICP during the first year of treatment were 
related to subsequent changes in LV mass index after 2 and 3 years of treatment in patients 
randomized to losartan, but not atenolol [26]. Losartan-related reduction in procollagen was 
shown to be greater in patients with higher baseline levels (those with hypertension and 
severe myocardial fibrosis) [150] and was significantly associated with symptom 
improvement [151]. 
4.7. TNF-α and IL-6 
The effects of antihypertensive drugs on the inflammatory biomarker TNF-α have been 
somewhat variable. In patients with hypertension, olmesartan medoxomil reduced TNF-α 
levels in one study [152], but in another study in Japanese patients, neither losartan nor the 
CCB amlodipine significantly affected TNF-α levels [147]. In obese hypertensive patients, 
telmisartan, but not losartan treatment, was shown to reduce serum TNF-α levels [132]. 
Conversely, another study showed that in newly diagnosed hypertension patients, losartan 
lowers TNF-α levels [117]. In chronic heart failure patients, the addition of losartan to ACEI 
therapy resulted in a significant reduction of TNF-α levels [140]. Amlodipine was effective 
in reducing TNF-α, but was significantly more effective when combined with atorvastatin 
[153]. Another study found no difference between losartan and amlodipine in TNF-α levels 
after treatment, but the investigators did not appear to perform baseline assessments in 
order to determine if either drug reduced TNF-α from baseline levels [118]. Manidipine and 
lisinopril combination therapy was shown to have a highly significant effect on TNF-α 
levels in non-diabetic, hypertensive patients with the metabolic syndrome [113]. 
 Insulin Resistance 252 
Losartan therapy significantly reduced TNF-α in patients with hypertension and T2DM 
[154]. However, olmesartan medoxomil combined with HCTZ had no effect on TNF-α in 
patients with hypertension and the metabolic syndrome (without diabetes), but when 
olmesartan medoxomil was combined with amlodipine, the combination did significantly 
reduce TNF-α levels [108]. Amlodipine was shown to reduce serum TNF-α levels, as well as 
mRNA expression of TNF-α in hypertensives with and without diabetes [155]. Interestingly, 
amlodipine alone was shown in another study to have no effect on TNF-α levels in patients 
with hypertension and the metabolic syndrome, whereas manidipine monotherapy was 
effective in lowering TNF-α [122]. Olmesartan medoxomil had no effect on TNF-α levels in 
patients with stage 3 or 4 CKD [107], and TNF-α was unaffected by amlodipine or 
spironolactone in patients with diabetic nephropathy [133]. 
Studies investigating the effect of antihypertensive drugs on IL-6 levels are summarized 
here. In an open-labeled study, losartan therapy reduced IL-6 levels in recently diagnosed 
hypertension without other CV disease risk factors [117]. Olmesartan medoxomil reduced 
IL-6 levels in one study in patients with hypertension [152], but had no effect in patients 
with stage 3 or 4 CKD [107]. Olmesartan medoxomil was ineffective when combined with 
HCTZ in patients with hypertension and the metabolic syndrome, but was effective in these 
patients when combined with amlodipine [108]. Valsartan combined with HCTZ was more 
effective than amlodipine alone in reducing IL-6 [156]. Another study showed that diabetics 
with hypertension have higher IL-6 levels than non-diabetics with hypertension, and 
amlodipine reduced serum IL-6 as well as mRNA expression of IL-6 in diabetics and non-
diabtetics [155]. In a crossover study with non-diabetic hypertensive patients, IL-6 levels 
were reduced with azelnidipine therapy, but not with amlodipine [112]. In the MARCADOR 
study, the greatest reduction in IL-6 was achieved with a combination of manidipine and 
lisinopril, while there was no change in IL-6 with amlodipine [113]. Another study found a 
greater reduction in IL-6 with benidipine treatment as compared to amlodipine treatment 
[100]. Losartan, as add-on therapy has also been shown to reduce IL-6 levels [140]. 
These cytokines are rather non-specific for quantification of inflammation; however, these 
studies do reflect the general state of inflammation in the vasculature. Clinical studies that 
measure the level of the cytokines demonstrate variable results. Multiple studies with 
antihypertensives indicate a general reduction in the levels of cytokines, suggesting a 
decrease in vascular inflammation. In context with the clinical situation and other risk 
factors, the measurement of these biomarkers may be useful. 
5. Conclusions 
It can be expected that biomarkers will continue to play an increasing role in the 
management of CV disease. Their importance or significance is likely to increase in direct 
proportion to the growth in our knowledge of disease pathophysiology and the mechanisms 
of drug action. The use of biomarkers does, however, depend upon the markers being 
accurate, relevant to the purpose, easy to measure, and consistently reproducible. 
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There is a wealth of evidence for improvement of validated biomarkers of vascular disease 
with most classes of antihypertensive treatment in a range of high-risk patient populations. 
These include obese patients, patients with diabetes, patients with renal disease and/or 
metabolic syndrome, existing vascular disease, and African American patients. Benefits 
have also been observed in those with normal BP, but with other CV risk factors. There is 
some evidence to suggest that at least part of the effect seen with some antihypertensives on 
these biomarkers may be independent of BP reduction. Different drugs may have quite 
different effects on biomarkers, despite very similar or equivalent effects on BP. However, 
with other drugs, the changes in certain biomarkers appear to parallel changes in BP. In 
addition, there appear to be clear associations between certain biomarkers, such as HOMA-
IR and adiponectin, and the manner in which they are affected by certain antihypertensive 
drugs.  
There is particularly compelling evidence that RAS inhibitors (ACEIs and ARBs) and CCBs 
may have beneficial effects beyond BP control, making them particularly attractive for either 
monotherapy or combination therapy. In contrast, other drugs, such as the thiazide diuretic 
HCTZ, appear to counter the beneficial effects on biomarkers normally observed with ARBs 
when they are used in combination.  
Of the biomarkers selected for review in this chapter, the benefits of antihypertensive 
therapy on hsCRP, adiponectin, and HOMA-IR reflect a potential for quantifiable long-term 
vascular benefits. However, more evidence is required to elucidate the mechanisms 
involved and understand the variability and apparent anomalies observed. In addition, 
more information about any differences between specific antihypertensive agents within the 
same class is needed. Additional evidence is required to determine the relevance of 
improvements observed with antihypertensive therapy on CAP, cystatin C, procollagen, 
TNF-α, and IL-6 to a reduction in the risk of subsequent vascular events. 
Further research is required to determine the extent to which these antihypertensive-related 
improvements in biomarkers contribute to the overall clinical outcome achieved in tandem 
with other CV risk reduction strategies and interventions. In addition, long-term studies 
with biomarkers are also required to show whether biomarkers correlate with long-term 
clinical outcomes. 
Author details 
Nadya Merchant and Bobby V. Khan 
Atlanta Vascular Research Foundation, Atlanta, GA, USA 
6. References 
[1] Writing Group, M., et al., Heart disease and stroke statistics--2010 update: a report from 
the American Heart Association. Circulation, 2010. 121(7): p. e46-e215. 
 Insulin Resistance 254 
[2] Packard, R.R. and P. Libby, Inflammation in atherosclerosis: from vascular biology to 
biomarker discovery and risk prediction. Clin Chem, 2008. 54(1): p. 24-38. 
[3] Maisel, A.S., Cardiovascular and renal surrogate markers in the clinical management of 
hypertension. Cardiovasc Drugs Ther, 2009. 23(4): p. 317-26. 
[4] Vasan, R.S., Biomarkers of cardiovascular disease: molecular basis and practical 
considerations. Circulation, 2006. 113(19): p. 2335-62. 
[5] Lambers Heerspink, H.J., V. Perkovic, and D. de Zeeuw, Renal and cardio-protective 
effects of direct renin inhibition: a systematic literature review. J Hypertens, 2009. 
27(12): p. 2321-31. 
[6] Novo, S., et al., Role of ARBs in the blood hypertension therapy and prevention of 
cardiovascular events. Curr Drug Targets, 2009. 10(1): p. 20-5. 
[7] Sola, S., et al., Irbesartan and lipoic acid improve endothelial function and reduce 
markers of inflammation in the metabolic syndrome: results of the Irbesartan and 
Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation, 2005. 111(3): p. 
343-8. 
[8] Nagamia, S., et al., The role of quinapril in the presence of a weight loss regimen: 
endothelial function and markers of obesity in patients with the metabolic syndrome. 
Prev Cardiol, 2007. 10(4): p. 204-9. 
[9] Persson, F., et al., Irbesartan treatment reduces biomarkers of inflammatory activity in 
patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes, 
2006. 55(12): p. 3550-5. 
[10] Derosa, G., et al., Candesartan effect on inflammation in hypertension. Hypertens Res, 
2010. 33(3): p. 209-13. 
[11] Shurtz-Swirski, R., et al., [The effect of calcium channel blocker lercanidipine on 
lowgrade inflammation parameters in essential hypertension patients]. Harefuah, 2006. 
145(12): p. 895-9, 942. 
[12] Komoda, H., T. Inoue, and K. Node, Anti-inflammatory properties of azelnidipine, a 
dihydropyridine-based calcium channel blocker. Clin Exp Hypertens, 2010. 32(2): p. 
121-8. 
[13] Merchant, N., et al., Effects of nebivolol in obese African Americans with hypertension 
(NOAAH): markers of inflammation and obesity in response to exercise-induced stress. 
J Hum Hypertens, 2011. 25(3): p. 196-202. 
[14] Del Fiorentino, A., et al., The effect of angiotensin receptor blockers on C-reactive 
protein and other circulating inflammatory indices in man. Vasc Health Risk Manag, 
2009. 5(1): p. 233-42. 
[15] Polonia, J., et al., Different influences on central and peripheral pulse pressure, aortic 
wave reflections and pulse wave velocity of three different types of antihypertensive 
drugs. Rev Port Cardiol, 2003. 22(12): p. 1485-92. 
[16] Karalliedde, J., et al., Valsartan improves arterial stiffness in type 2 diabetes 
independently of blood pressure lowering. Hypertension, 2008. 51(6): p. 1617-23. 
[17] Ridker, P.M., et al., Valsartan, blood pressure reduction, and C-reactive protein: 
primary report of the Val-MARC trial. Hypertension, 2006. 48(1): p. 73-9. 
 
The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control 255 
[18] Bloch, M.J., Do angiotensin receptor antagonists decrease hsCRP independent of blood 
pressure - and does it matter? J Clin Hypertens (Greenwich), 2007. 9(1): p. 57-9. 
[19] Futai, R., et al., Olmesartan ameliorates myocardial function independent of blood 
pressure control in patients with mild-to-moderate hypertension. Heart Vessels, 2009. 
24(4): p. 294-300. 
[20] Moriuchi, A., et al., Induction of human adiponectin gene transcription by telmisartan, 
angiotensin receptor blocker, independently on PPAR-gamma activation. Biochem 
Biophys Res Commun, 2007. 356(4): p. 1024-30. 
[21] Schepke, M., et al., Hemodynamic effects of the angiotensin II receptor antagonist 
irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology, 2001. 
121(2): p. 389-95. 
[22] Watanabe, S., et al., Valsartan reduces serum cystatin C and the renal vascular 
resistance in patients with essential hypertension. Clin Exp Hypertens, 2006. 28(5): p. 
451-61. 
[23] Derosa, G., et al., Metabolic effects of telmisartan and irbesartan in type 2 diabetic 
patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther, 2007. 
32(3): p. 261-8. 
[24] Usui, I., et al., Telmisartan reduced blood pressure and HOMA-IR with increasing 
plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin 
Pract, 2007. 77(2): p. 210-4. 
[25] de Luis, D.A., et al., Effects of telmisartan vs olmesartan on metabolic parameters, 
insulin resistance and adipocytokines in hypertensive obese patients. Nutr Hosp, 2010. 
25(2): p. 275-9. 
[26] Christensen, M.K., et al., Does long-term losartan- vs atenolol-based antihypertensive 
treatment influence collagen markers differently in hypertensive patients? A LIFE 
substudy. Blood Press, 2006. 15(4): p. 198-206. 
[27] Muller-Brunotte, R., et al., Myocardial fibrosis and diastolic dysfunction in patients 
with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy 
Investigation versus Atenolol (SILVHIA). J Hypertens, 2007. 25(9): p. 1958-66. 
[28] Kawamura, M., et al., Candesartan decreases type III procollagen-N-peptide levels and 
inflammatory marker levels and maintains sinus rhythm in patients with atrial 
fibrillation. J Cardiovasc Pharmacol, 2010. 55(5): p. 511-7. 
[29] Fogari, R., et al., Effects of amlodipine-atorvastatin combination on inflammation 
markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. 
Eur J Clin Pharmacol, 2006. 62(10): p. 817-22. 
[30] Fujita, M., et al., Blockade of angiotensin II receptors reduces the expression of receptors 
for advanced glycation end products in human endothelial cells. Arterioscler Thromb 
Vasc Biol, 2006. 26(10): p. e138-42. 
[31] Schulz, R. and G. Heusch, Tumor necrosis factor-alpha and its receptors 1 and 2: Yin 
and Yang in myocardial infarction? Circulation, 2009. 119(10): p. 1355-7. 
[32] Cesari, M., et al., Inflammatory markers and onset of cardiovascular events: results 
from the Health ABC study. Circ
 Insulin Resistance 256 
[33] Luc, G., et al., C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary 
heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol, 2003. 23(7): p. 1255-61. 
[34] Pai, J.K., et al., Inflammatory markers and the risk of coronary heart disease in men and 
women. N Engl J Med, 2004. 351(25): p. 2599-610. 
[35] Patarroyo Aponte, M.M. and G.S. Francis, Effect of Angiotensin-Converting Enzyme 
Inhibitors and Angiotensin Receptor Antagonists in Atherosclerosis Prevention. Curr 
Cardiol Rep, 2012. 
[36] Lonn, E., Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers 
in atherosclerosis. Curr Atheroscler Rep, 2002. 4(5): p. 363-72. 
[37] Shahin, Y., et al., Angiotensin converting enzyme inhibitors effect on endothelial 
dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis, 2011. 
216(1): p. 7-16. 
[38] Yusuf, S., [After the HOPE Study. ACE inhibitor now for every diabetic patient?. 
Interview by Dr. Dirk Einecke]. MMW Fortschr Med, 2000. 142(44): p. 10. 
[39] Fox, K.M. and E.U.t.O.r.o.c.e.w.P.i.s.c.A.d. Investigators, Efficacy of perindopril in 
reduction of cardiovascular events among patients with stable coronary artery disease: 
randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). 
Lancet, 2003. 362(9386): p. 782-8. 
[40] PROGRESS will change the way we view stroke treatment. Cardiovasc J S Afr, 2001. 
12(5): p. 288. 
[41] Dahlof, B., et al., Prevention of cardiovascular events with an antihypertensive regimen 
of amlodipine adding perindopril as required versus atenolol adding 
bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-
Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled 
trial. Lancet, 2005. 366(9489): p. 895-906. 
[42] Dzau, V.J., Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular 
disease: a unifying hypothesis. Hypertension, 2001. 37(4): p. 1047-52. 
[43] Dzau, V.J., et al., The relevance of tissue angiotensin-converting enzyme: manifestations 
in mechanistic and endpoint data. Am J Cardiol, 2001. 88(9A): p. 1L-20L. 
[44] Investigators, O., et al., Telmisartan, ramipril, or both in patients at high risk for 
vascular events. N Engl J Med, 2008. 358(15): p. 1547-59. 
[45] Velazquez, E.J., et al., VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: 
baseline characteristics in context. Eur J Heart Fail, 2003. 5(4): p. 537-44. 
[46] Dahlof, B., et al., Effects of losartan and atenolol on left ventricular mass and 
neurohormonal profile in patients with essential hypertension and left ventricular 
hypertrophy. J Hypertens, 2002. 20(9): p. 1855-64. 
[47] Koh, K.K., et al., Additive beneficial effects of losartan combined with simvastatin in the 
treatment of hypercholesterolemic, hypertensive patients. Circulation, 2004. 110(24): p. 
3687-92. 
[48] Turnbull, F. and C. Blood Pressure Lowering Treatment Trialists, Effects of different 
blood-pressure-lowering regimens on major cardiovascular events: results of 
prospectively-designed overviews of randomised trials. Lancet, 2003. 362(9395): p. 1527-
35. 
 
The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control 257 
[49] Messerli, F.H., Calcium antagonists and beta-blockers: impact on cardiovascular and 
cerebrovascular events. Clin Cornerstone, 2004. 6(4): p. 18-27. 
[50] Williams, B., et al., Differential impact of blood pressure-lowering drugs on central 
aortic pressure and clinical outcomes: principal results of the Conduit Artery Function 
Evaluation (CAFE) study. Circulation, 2006. 113(9): p. 1213-25. 
[51] Terai, M., et al., Comparison of arterial functional evaluations as a predictor of 
cardiovascular events in hypertensive patients: the Non-Invasive Atherosclerotic 
Evaluation in Hypertension (NOAH) study. Hypertens Res, 2008. 31(6): p. 1135-45. 
[52] Luna, B. and M.N. Feinglos, Drug-induced hyperglycemia. JAMA, 2001. 286(16): p. 
1945-8. 
[53] Bangalore, S., et al., A meta-analysis of 94,492 patients with hypertension treated with 
beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol, 2007. 
100(8): p. 1254-62. 
[54] Dahlof, B., et al., Cardiovascular morbidity and mortality in the Losartan Intervention 
For Endpoint reduction in hypertension study (LIFE): a randomised trial against 
atenolol. Lancet, 2002. 359(9311): p. 995-1003. 
[55] Wright, J.T., Jr., et al., Lowering blood pressure with beta-blockers in combination with 
other renin-angiotensin system blockers in patients with hypertension and type 2 
diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich), 2007. 9(11): p. 
842-9. 
[56] Bakris, G.L., et al., Metabolic effects of carvedilol vs metoprolol in patients with type 2 
diabetes mellitus and hypertension: a randomized controlled trial. JAMA, 2004. 292(18): 
p. 2227-36. 
[57] Agabiti Rosei, E. and D. Rizzoni, Metabolic profile of nebivolol, a beta-adrenoceptor 
antagonist with unique characteristics. Drugs, 2007. 67(8): p. 1097-107. 
[58] Chobanian, A.V., et al., The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 
report. JAMA, 2003. 289(19): p. 2560-72. 
[59] Prevention of stroke by antihypertensive drug treatment in older persons with isolated 
systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program 
(SHEP). SHEP Cooperative Research Group. JAMA, 1991. 265(24): p. 3255-64. 
[60] Sica, D.A., et al., Thiazide and loop diuretics. J Clin Hypertens (Greenwich), 2011. 13(9): 
p. 639-43. 
[61] Materson, B.J., et al., Results of combination anti-hypertensive therapy after failure of 
each of the components. Department of Veterans Affairs Cooperative Study Group on 
Anti-hypertensive Agents. J Hum Hypertens, 1995. 9(10): p. 791-6. 
[62] Fisher, N.D. and N.K. Hollenberg, Renin inhibition: what are the therapeutic 
opportunities? J Am Soc Nephrol, 2005. 16(3): p. 592-9. 
[63] Brown, N.J., Aldosterone and vascular inflammation. Hypertension, 2008. 51(2): p. 161-
7. 
[64] Farquharson, C.A. and A.D. Struthers, Spironolactone increases nitric oxide bioactivity, 
improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin 
 Insulin Resistance 258 
I/angiotensin II conversion in patients with chronic heart failure. Circulation, 2000. 
101(6): p. 594-7. 
[65] Parving, H.H., et al., Aliskiren combined with losartan in type 2 diabetes and 
nephropathy. N Engl J Med, 2008. 358(23): p. 2433-46. 
[66] Cleland, J.G., et al., Clinical trials update from the European Society of Cardiology 
Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure. Eur J Heart Fail, 
2007. 9(10): p. 1070-3. 
[67] Wang, X., et al., Assessment of arterial stiffness, a translational medicine biomarker 
system for evaluation of vascular risk. Cardiovasc Ther, 2008. 26(3): p. 214-23. 
[68] Williams, B. and P.S. Lacy, Central aortic pressure and clinical outcomes. J Hypertens, 
2009. 27(6): p. 1123-5. 
[69] Nelson, M.R., et al., Noninvasive measurement of central vascular pressures with 
arterial tonometry: clinical revival of the pulse pressure waveform? Mayo Clin Proc, 
2010. 85(5): p. 460-72. 
[70] Paoletti, R., A.M. Gotto, Jr., and D.P. Hajjar, Inflammation in atherosclerosis and 
implications for therapy. Circulation, 2004. 109(23 Suppl 1): p. III20-6. 
[71] Black, S., I. Kushner, and D. Samols, C-reactive Protein. J Biol Chem, 2004. 279(47): p. 
48487-90. 
[72] Bautista, L.E., et al., Association between C-reactive protein and hypertension in 
healthy middle-aged men and women. Coron Artery Dis, 2004. 15(6): p. 331-6. 
[73] Dauphinot, V., et al., C-reactive protein implications in new-onset hypertension in a 
healthy population initially aged 65 years: the Proof study. J Hypertens, 2009. 27(4): p. 
736-43. 
[74] Abramson, J.L., W.S. Weintraub, and V. Vaccarino, Association between pulse pressure 
and C-reactive protein among apparently healthy US adults. Hypertension, 2002. 39(2): 
p. 197-202. 
[75] Genest, J., Preventive cardiology: move over low density lipoprotein cholesterol, hello 
C-reactive protein? Can J Cardiol, 2004. 20 Suppl B: p. 89B-92B. 
[76] Savoia, C. and E.L. Schiffrin, Reduction of C-reactive protein and the use of anti-
hypertensives. Vasc Health Risk Manag, 2007. 3(6): p. 975-83. 
[77] Montecucco, F. and F. Mach, Update on therapeutic strategies to increase adiponectin 
function and secretion in metabolic syndrome. Diabetes Obes Metab, 2009. 11(5): p. 445-
54. 
[78] Karthikeyan, V.J. and G.Y. Lip, Antihypertensive treatment, adiponectin and 
cardiovascular risk. J Hum Hypertens, 2007. 21(1): p. 8-11. 
[79] Shargorodsky, M., et al., Adiponectin and vascular properties in obese patients: is it a 
novel biomarker of early atherosclerosis? Int J Obes (Lond), 2009. 33(5): p. 553-8. 
[80] Makita, S., et al., Potential effects of angiotensin II receptor blockers on glucose 
tolerance and adiponectin levels in hypertensive patients. Cardiovasc Drugs Ther, 2007. 
21(4): p. 317-8. 
[81] Ylinen, E.A., et al., Cystatin C as a marker for glomerular filtration rate in pediatric 
patients. Pediatr Nephrol, 1999. 13(6): p. 506-9. 
 
The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control 259 
[82] Laterza, O.F., C.P. Price, and M.G. Scott, Cystatin C: an improved estimator of 
glomerular filtration rate? Clin Chem, 2002. 48(5): p. 699-707. 
[83] Massey, D., Commentary: clinical diagnostic use of cystatin C. J Clin Lab Anal, 2004. 
18(1): p. 55-60. 
[84] Kniepeiss, D., et al., Serum cystatin C is an easy to obtain biomarker for the onset of 
renal impairment in heart transplant recipients. J Thorac Cardiovasc Surg, 2010. 
[85] Mena, C., et al., Cystatin c and blood pressure: results of 24 h ambulatory blood 
pressure monitoring. Eur J Intern Med, 2010. 21(3): p. 185-90. 
[86] Prats, M., et al., Cystatin C and cardiac hypertrophy in primary hypertension. Blood 
Press, 2010. 19(1): p. 20-5. 
[87] Matthews, D.R., et al., Homeostasis model assessment: insulin resistance and beta-cell 
function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 
1985. 28(7): p. 412-9. 
[88] Cooper-DeHoff, R.M., M.A. Pacanowski, and C.J. Pepine, Cardiovascular therapies and 
associated glucose homeostasis: implications across the dysglycemia continuum. J Am 
Coll Cardiol, 2009. 53(5 Suppl): p. S28-34. 
[89] Szmigielski, C., et al., Metabolism of collagen is altered in hypertensives with increased 
intima media thickness. Blood Press, 2006. 15(3): p. 157-63. 
[90] Ishikawa, J., et al., Collagen metabolism in extracellular matrix may be involved in 
arterial stiffness in older hypertensive patients with left ventricular hypertrophy. 
Hypertens Res, 2005. 28(12): p. 995-1001. 
[91] Lopez, B., et al., The use of collagen-derived serum peptides for the clinical assessment 
of hypertensive heart disease. J Hypertens, 2005. 23(8): p. 1445-51. 
[92] Cesari, M., et al., Inflammatory markers and cardiovascular disease (The Health, Aging 
and Body Composition [Health ABC] Study). Am J Cardiol, 2003. 92(5): p. 522-8. 
[93] Williams, B., et al., Differential impact of blood pressure-lowering drugs on central 
aortic pressure and clinical outcomes: principal results of the Conduit Artery Function 
Evaluation (CAFE) study. Circulation, 2006. 113(9): p. 1213-25. 
[94] Neal, D.A., et al., Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in 
hypertensive patients after liver transplantation. Transplantation, 2004. 77(5): p. 748-50. 
[95] Takami, T. and Y. Saito, Effects of Azelnidipine plus OlmesaRTAn versus amlodipine 
plus olmesartan on central blood pressure and left ventricular mass index: the AORTA 
study. Vasc Health Risk Manag, 2011. 7: p. 383-90. 
[96] Morgan, T., et al., Effect of different antihypertensive drug classes on central aortic 
pressure. Am J Hypertens, 2004. 17(2): p. 118-23. 
[97] Kagota, S., et al., Peroxynitrite is Involved in the dysfunction of vasorelaxation in 
SHR/NDmcr-cp rats, spontaneously hypertensive obese rats. J Cardiovasc Pharmacol, 
2007. 50(6): p. 677-85. 
[98] Ferguson, J.M., et al., Effects of a fixed-dose ACE inhibitor-diuretic combination on 
ambulatory blood pressure and arterial properties in isolated systolic hypertension. J 
Cardiovasc Pharmacol, 2008. 51(6): p. 590-5. 
 Insulin Resistance 260 
[99] Ishii, H., T. Tsukada, and M. Yoshida, Angiotensin II type-I receptor blocker, 
candesartan, improves brachial-ankle pulse wave velocity independent of its blood 
pressure lowering effects in type 2 diabetes patients. Intern Med, 2008. 47(23): p. 2013-8. 
[100] Nakamura, M., et al., Brachial-ankle pulse wave velocity as a risk stratification index 
for the short-term prognosis of type 2 diabetic patients with coronary artery disease. 
Hypertens Res, 2010. 33(10): p. 1018-24. 
[101] Kinouchi, K., et al., Differential Effects in Cardiovascular Markers between High-Dose 
Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with 
Calcium Channel Blocker in Hypertension (DEAR Trial). Int J Hypertens, 2011. 2011: p. 
284823. 
[102] Miyoshi, T., et al., Olmesartan reduces arterial stiffness and serum adipocyte fatty 
acid-binding protein in hypertensive patients. Heart Vessels, 2011. 26(4): p. 408-13. 
[103] Takiguchi, S., et al., Olmesartan improves endothelial function in hypertensive 
patients: link with extracellular superoxide dismutase. Hypertens Res, 2011. 34(6): p. 
686-92. 
[104] Koh, K.K., et al., Additive beneficial effects of atorvastatin combined with amlodipine 
in patients with mild-to-moderate hypertension. Int J Cardiol, 2011. 146(3): p. 319-25. 
[105] Li, M., et al., Impact of combination therapy with amlodipine and atorvastatin on 
plasma adiponectin levels in hypertensive patients with coronary artery disease: 
combination therapy and adiponectin. Postgrad Med, 2011. 123(6): p. 66-71. 
[106] Yilmaz, R., et al., Impact of amlodipine or ramipril treatment on left ventricular mass 
and carotid intima-media thickness in nondiabetic hemodialysis patients. Ren Fail, 
2010. 32(8): p. 903-12. 
[107] de Vinuesa, S.G., et al., Insulin resistance, inflammatory biomarkers, and adipokines in 
patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc 
Nephrol, 2006. 17(12 Suppl 3): p. S206-12. 
[108] Martinez-Martin, F.J., et al., Olmesartan/amlodipine vs 
olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the 
OLAS study. J Hum Hypertens, 2011. 25(6): p. 346-53. 
[109] Derosa, G., et al., Differential effects of candesartan and olmesartan on adipose tissue 
activity biomarkers in type II diabetic hypertensive patients. Hypertens Res, 2010. 33(8): 
p. 790-5. 
[110] Doi, M., et al., Combination therapy of calcium channel blocker and angiotensin II 
receptor blocker reduces augmentation index in hypertensive patients. Am J Med Sci, 
2010. 339(5): p. 433-9. 
[111] Ishimitsu, T., et al., Angiotensin-II receptor antagonist combined with calcium channel 
blocker or diuretic for essential hypertension. Hypertens Res, 2009. 32(11): p. 962-8. 
[112] Fukao, K., et al., Effects of calcium channel blockers on glucose tolerance, 
inflammatory state, and circulating progenitor cells in non-diabetic patients with 
essential hypertension: a comparative study between Azelnidipine and amlodipine on 
glucose tolerance and endothelial function - a crossover trial (AGENT). Cardiovasc 
Diabetol, 2011. 10: p. 79. 
 
The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control 261 
[113] Martinez-Martin, F.J., et al., Effects of manidipine and its combination with an ACE 
inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic 
markers in hypertensive patients with metabolic syndrome: the MARCADOR study. 
Clin Drug Investig, 2011. 31(3): p. 201-12. 
[114] Igarashi, M., et al., Dual blockade of angiotensin II with enalapril and losartan reduces 
proteinuria in hypertensive patients with type 2 diabetes. Endocr J, 2006. 53(4): p. 493-
501. 
[115] Matsui, Y., et al., Urinary albumin excretion during angiotensin II receptor blockade: 
comparison of combination treatment with a diuretic or a calcium-channel blocker. Am 
J Hypertens, 2011. 24(4): p. 466-73. 
[116] Sugihara, M., et al., Safety and efficacy of antihypertensive therapy with add-on 
angiotensin II type 1 receptor blocker after successful coronary stent implantation. 
Hypertens Res, 2009. 32(7): p. 625-30. 
[117] Sardo, M.A., et al., Effects of the angiotensin II receptor blocker losartan on the 
monocyte expression of biglycan in hypertensive patients. Clin Exp Pharmacol Physiol, 
2010. 37(9): p. 933-8. 
[118] Aksnes, T.A., et al., Improved insulin sensitivity by the angiotensin II-receptor blocker 
losartan is not explained by adipokines, inflammatory markers, or whole blood 
viscosity. Metabolism, 2007. 56(11): p. 1470-7. 
[119] Ruilope, L.M., et al., Efficacy and tolerability of combination therapy with valsartan 
plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive 
patients with other cardiovascular risk factors: the VAST study. Clin Ther, 2005. 27(5): 
p. 578-87. 
[120] Tomiyama, H., et al., Discrepancy between improvement of insulin sensitivity and that 
of arterial endothelial function in patients receiving antihypertensive medication. J 
Hypertens, 2007. 25(4): p. 883-9. 
[121] Navalkar, S., et al., Irbesartan, an angiotensin type 1 receptor inhibitor, regulates 
markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol, 
2001. 37(2): p. 440-4. 
[122] Martinez Martin, F.J., Manidipine in hypertensive patients with metabolic syndrome: 
the MARIMBA study. Expert Rev Cardiovasc Ther, 2009. 7(7): p. 863-9. 
[123] Masajtis-Zagajewska, A., J. Majer, and M. Nowicki, Effect of moxonidine and 
amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant 
hypertensive patients-a randomized, crossover trial. Hypertens Res, 2010. 33(4): p. 348-
53. 
[124] Ge, C.J., et al., Synergistic effect of amlodipine and atorvastatin on blood pressure, left 
ventricular remodeling, and C-reactive protein in hypertensive patients with primary 
hypercholesterolemia. Heart Vessels, 2008. 23(2): p. 91-5. 
[125] Rizos, C.V., et al., Combining rosuvastatin with sartans of different peroxisome 
proliferator-activated receptor-gamma activating capacity is not associated with 
different changes in low-density lipoprotein subfractions and plasma lipoprotein-
associated phospholipase A(2). Metab Syndr Relat Disord, 2011. 9(3): p. 217-23. 
 Insulin Resistance 262 
[126] Negro, R., G. Formoso, and H. Hassan, The effects of irbesartan and telmisartan on 
metabolic parameters and blood pressure in obese, insulin resistant, hypertensive 
patients. J Endocrinol Invest, 2006. 29(11): p. 957-61. 
[127] Kintscher, U., et al., Irbesartan for the treatment of hypertension in patients with the 
metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. 
Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol, 
2007. 6: p. 12. 
[128] Krikken, J.A., et al., Antiproteinuric therapy decreases LDL-cholesterol as well as 
HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl 
ester transfer protein mass and adiponectin. Expert Opin Ther Targets, 2009. 13(5): p. 
497-504. 
[129] Negro, R. and H. Hassan, The effects of telmisartan and amlodipine on metabolic 
parameters and blood pressure in type 2 diabetic, hypertensive patients. J Renin 
Angiotensin Aldosterone Syst, 2006. 7(4): p. 243-6. 
[130] Nishimura, H., et al., Losartan elevates the serum high-molecular weight-adiponectin 
isoform and concurrently improves insulin sensitivity in patients with impaired glucose 
metabolism. Hypertens Res, 2008. 31(8): p. 1611-8. 
[131] Derosa, G., et al., Different actions of losartan and ramipril on adipose tissue activity 
and vascular remodeling biomarkers in hypertensive patients. Hypertens Res, 2011. 
34(1): p. 145-51. 
[132] Huang, Y.Y., et al., [Effect of losartan on renal expression of monocyte chemoattractant 
protein-1 and transforming growth factor-beta(1) in rats after unilateral ureteral 
obstruction]. Nan Fang Yi Ke Da Xue Xue Bao, 2011. 31(8): p. 1405-10. 
[133] Matsumoto, S., K. Takebayashi, and Y. Aso, The effect of spironolactone on circulating 
adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic 
nephropathy. Metabolism, 2006. 55(12): p. 1645-52. 
[134] Piecha, G., et al., Indapamide decreases plasma adiponectin concentration in patients 
with essential hypertension. Kidney Blood Press Res, 2007. 30(3): p. 187-94. 
[135] Yilmaz, M.I., et al., Effect of antihypertensive agents on plasma adiponectin levels in 
hypertensive patients with metabolic syndrome. Nephrology (Carlton), 2007. 12(2): p. 
147-53. 
[136] Koh, K.K., et al., Distinct vascular and metabolic effects of different classes of anti-
hypertensive drugs. Int J Cardiol, 2010. 140(1): p. 73-81. 
[137] Guo, L.L., Y. Pan, and H.M. Jin, Adiponectin is positively associated with insulin 
resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 
1 receptor blocker losartan. Nephrol Dial Transplant, 2009. 24(6): p. 1876-83. 
[138] Albayrak, S., et al., Effect of olmesartan medoxomil on cystatin C level, left ventricular 
hypertrophy and diastolic function. Blood Press, 2009. 18(4): p. 187-91. 
[139] Koc, Y., et al., Effect of Olmesartan on serum cystatin C levels in the patients with 
essential hypertension. Eur Rev Med Pharmacol Sci, 2011. 15(12): p. 1389-94. 
[140] Ogino, K., et al., Addition of losartan to angiotensin-converting enzyme inhibitors 
improves insulin resistance in patients with chronic heart failure treated without beta-
blockers. Circ J, 2010. 74(11): p. 2346-52. 
 
The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control 263 
[141] Bahadir, O., et al., Effects of telmisartan and losartan on insulin resistance in 
hypertensive patients with metabolic syndrome. Hypertens Res, 2007. 30(1): p. 49-53. 
[142] Lan, J., et al., The relationship between visfatin and HOMA-IR in hypertensive 
patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in 
hypertensive patients with insulin resistance. Diabetes Res Clin Pract, 2011. 94(1): p. 71-
6. 
[143] De Luis, D.A., et al., Effects of olmesartan vs irbesartan on metabolic parameters and 
visfatin in hypertensive obese women. Eur Rev Med Pharmacol Sci, 2010. 14(9): p. 759-
63. 
[144] Dohi, T., et al., Effects of olmesartan on blood pressure and insulin resistance in 
hypertensive patients with sleep-disordered breathing. Heart Vessels, 2011. 26(6): p. 
603-8. 
[145] Enjoji, M., et al., Therapeutic effect of ARBs on insulin resistance and liver injury in 
patients with NAFLD and chronic hepatitis C: a pilot study. Int J Mol Med, 2008. 22(4): 
p. 521-7. 
[146] Jin, H.M. and Y. Pan, Angiotensin type-1 receptor blockade with losartan increases 
insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes 
and nephropathy. Nephrol Dial Transplant, 2007. 22(7): p. 1943-9. 
[147] Watanabe, S., et al., The effect of losartan and amlodipine on serum adiponectin in 
Japanese adults with essential hypertension. Clin Ther, 2006. 28(10): p. 1677-85. 
[148] Fogari, R., et al., Effect of valsartan and ramipril on atrial fibrillation recurrence and P-
wave dispersion in hypertensive patients with recurrent symptomatic lone atrial 
fibrillation. Am J Hypertens, 2008. 21(9): p. 1034-9. 
[149] Ishimitsu, T., et al., Protective effects of an angiotensin II receptor blocker and a long-
acting calcium channel blocker against cardiovascular organ injuries in hypertensive 
patients. Hypertens Res, 2005. 28(4): p. 351-9. 
[150] Diez, J., et al., Losartan-dependent regression of myocardial fibrosis is associated with 
reduction of left ventricular chamber stiffness in hypertensive patients. Circulation, 
2002. 105(21): p. 2512-7. 
[151] Dziadzio, M., et al., Losartan therapy for Raynaud's phenomenon and scleroderma: 
clinical and biochemical findings in a fifteen-week, randomized, parallel-group, 
controlled trial. Arthritis Rheum, 1999. 42(12): p. 2646-55. 
[152] Lorenzen, J.M., et al., Angiotensin II receptor blocker and statins lower elevated levels 
of osteopontin in essential hypertension--results from the EUTOPIA trial. 
Atherosclerosis, 2010. 209(1): p. 184-8. 
[153] Fogari, R., et al., Hydrochlorothiazide added to valsartan is more effective than when 
added to olmesartan in reducing blood pressure in moderately hypertensive patients 
inadequately controlled by monotherapy. Adv Ther, 2006. 23(5): p. 680-95. 
[154] Park, H., et al., Relationship between insulin resistance and inflammatory markers and 
anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. 
Clin Chim Acta, 2006. 374(1-2): p. 129-34. 
 Insulin Resistance 264 
[155] Navarro-Gonzalez, J., et al., Serum and gene expression profile of tumor necrosis 
factor-alpha and interleukin-6 in hypertensive diabetic patients: effect of amlodipine 
administration. Int J Immunopathol Pharmacol, 2010. 23(1): p. 51-9. 
[156] Ruilope, L.M., et al., 24-hour ambulatory blood-pressure effects of valsartan and 
hydrochlorothiazide combinations compared with amlodipine in hypertensive patients 
at increased cardiovascular risk: a VAST sub-study. Blood Press Monit, 2005. 10(2): p. 
85-91. 
